SII is part of the agreement with AstraZeneca, which along with Oxford University has developed a vaccine that has reported satisfactory progress from the test results.
Adar Poonawalla, Chief Executive Officer of Pune-based Serum Institute of India (SII), has said the coronavirus vaccine may be ready by the end of this year and that the final price of the anti-virus dose will be announced in two months.
SII is part of an agreement with AstraZeneca, which along with Oxford University, has developed a vaccine that has reported satisfactory progress from the test results.
"We should have a vaccine by the end of this year. We will conduct trials in India on a few thousand patients in partnership with the Indian Council of Medical Research (ICMR)," Poonawalla told CNBC-TV18, adding the final pricing for the vaccine will be announced in two months.
Poonawalla had earlier said that by the end of August, between 4,000 to 5,000 people in Pune and Mumbai will be injected with the vaccine as part of trials scheduled to last over two month. He said the company aims to manufacture 300 million to 400 million doses by the year-end.
The institute has also inked a pact with the Bill and Melinda Gates Foundation and Gavi, The Vaccine Alliance, to make 100 million doses of the vaccine. This is for low-and medium-income countries, and with a price cap of Rs 250 a dose.
Source - News18
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
SERUM INSTITUTE OF INDIA TO PRODUCE UP TO AN ADDITIONAL 100 MILLION COVID-19 VACCINE DOSES FOR INDIA AND LOW-AND MIDDLE-INCOME COUNTRIES IN 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.